History

Oct. 1995 Founded in Nishi-Shimbashi, Minato-ku, Tokyo, with the aim of providing a new medical support business in preventive medicine (capital:JPY10 million).
Apr. 1999 Established Institute of Molecular Immunology in Seta, Setagaya-ku, Tokyo, constructed Cell Processing Center for Seta Clinic (Seta CPC), and started providing its core business Immuno-Cell Therapy Total Support Service.
Dec. 2000 Relocated its Head Office to Shimbashi, Minato-ku, Tokyo.
Aug. 2001 Ministry of Health, Labour and Welfare approved "Project for development ofnew business fields" under the Act for Facilitating the Creation of New Business.
Oct. 2001 Relocated its Head Office to Shin-Yokohama, Kohoku-ku, Yokohama, constructed Shin-Yokohama CPC1, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions.
Apr. 2002 Established Institute of Medical Science at Kohoku-ku, Yokohama-shi, Kanagawa.
Jul. 2002 Established Shin-Yokohama CPC2 for contracted Medical Institutions.
May 2003 Newly established Research and Development Center at Tamagawadai, Setagaya-ku, Tokyo. Transferred the Institute of Molecular Immunology and the Institute of Medical Science to the new institute, and renamed the latter to “Institute of Molecular Genetics.”
Jun. 2003 Established Osaka Office in Esaka-cho, Suita-shi, Osaka, constructed Osaka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions.
Jul. 2003 Received 1st "Courageous Management Award" sponsored by the Tokyo Chamber of Commerce and Industry.
Oct. 2003 Established Fukuoka Office in Hakata-ku, Fukuoka-city, constructed Fukuoka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions.
MEDINET's shares were listed on Tokyo Stock Exchange (Mothers: 2370) (as of Oct. 8, 2003).
Mar. 2004 International Organization for Standardization certified ISO9001 Certification for quality management of cell culturing and processing.
May 2004 Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to "Medinet Medical Institute."
Aug. 2004 Started providing new cancer tissue storage service Self Cancer Cell Depository™.
Feb. 2007 Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the "Department of Immunotherapeutics" established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital.
Jun. 2007 Concluded a license agreement with the National Hospital Organization Osaka Medical Center for immuno-cell therapy technological support at the center.
Nov. 2007 Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to "Research and Development Center."
Jan. 2008 Established Institute of Medical Service Management, Inc.
Jul. 2011 Started Providing Immuno-Cell Therapy Total Support Service to Kyushu University's Center for Advanced Medical Innovation.
Apr. 2012 Established the cooperative research department "Department of Advanced Molecular and Cell Therapy" in Kyushu University Center for Advanced Medical Innovation.
Jul. 2012 Started providing its service to the University of Tokyo Hospital which provides autologous γδT lymphocytes in patients with non-small cell lung cancer as advanced medical treatment.
Dec. 2013 Established a wholly owned subsidiary "MEDcell Co., Ltd.", for the Cell Medicinal Product Business.
For expansion of the "Contract Cell Manufacturing Business," established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF).
May 2015 Obtained license for the manufacture of specified cell products in Shinagawa CPF.
Jun. 2016 Transferred the entire R&D function from Tamagawadai, Setagaya-ku, Tokyo to its Head Office.
Oct. 2016 Contracted cell processing business at Ibaraki Children's Hospital.
May. 2017 Agreement with the Kenkoigaku Association on the manufacture of specified cell products.
Oct. 2017 Received regulatory approval to manufacture specified cell products at its Shin-Yokohama Cell Processing Center and Osaka Cell Processing Center.
Oct. 2017 Agreement with Miwa Central Clinic regarding manufacturing of specified cell products.
Dec. 2017 Entered into license agreement with Histogenics Corporation for Development and Commercialization of NeoCart for the Japanese Market.
Mar. 2018 With the National Hospital Organization concluded a joint development agreement with the goal of obtaining approval to manufacture and sell as a regenerative medicinal product ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL).
Aug. 2018 Integrated Osaka CPC into Shin-Yokohama CPC.
Aug. 2018 Conducted an absorption-type merger of two consolidated subsidiaries, Institute of Medical Service Management, Inc. and MEDcell Co., Ltd.
The merger took effect on October 1, 2018.
Dec. 2018 Signed a contract development agreement with JUNTEN BIO Co.,Ltd. for technology to manufacture regenerative medicinal products.
Jan. 2019 Concluded a licensing agreement with BioLegend, Inc., which is headquartered in the US, for the development of research products using one of our novel monoclonal antibodies.
Apr. 2019 Integrated Shin-Yokohama CPC into Shinagawa CPF.
Jun. 2019 Relocated its Head Office to Heiwajima, Ota-ku, Tokyo.
Oct. 2019 Signed a licensing agreement with Taiwanese listed biopharmaceutical company Medigen Biotechnology Corp. regarding gamma-delta T cell culture technology.
Oct. 2019 Signed a joint research agreement with the National Cancer Center.
Nov. 2019 Signed a joint research agreement with the Kyoto Prefectural University of Medicine and patent joint application.
Nov. 2019 Signed a joint research agreement with National University Corporation Kyushu University.
Jan. 2020 Obtained license for the manufacture of regenerative medicinal products in Shinagawa CPF.